Skip to main content
. Author manuscript; available in PMC: 2014 Jun 12.
Published in final edited form as: Leukemia. 2013 May 14;27(10):2075–2077. doi: 10.1038/leu.2013.148

Figure 1. Low CXCR4 expression is associated with bortezomib-resistance and poor clinical outcomes in patients treated with bortezomib.

Figure 1

(a) Fluorescence-activated cell sorting (FACS) analysis of BzS (solid black line) and BzR (dark gray histogram) mouse cells stained with a CXCR4 antibody for total (intracellular and cell surface) protein. (b) Survival analysis of high and low CXCR4 expressing MM patient groups taken from the APEX drug trial7 treated with either single-agent Bz (left panel) or high-dose dexamethasone (right panel). (c) Event-free (EFS; left panel) and overall survival (OS; right panel) analysis of high and low CXCR4 expressing MM patient groups taken from the total therapy 3 (MMTT3) drug trial.8 P values represent significant differences by one-way analysis of variance (P <0.05 was considered significant). The number of cases analyzed is indicated.